Approved Hospital Formulary
Add Formweb to your mobile device
Search results for:
natalizumab
natalizumab
Brand names: Tysabri
| Form | Strength |
|---|---|
| CONCENTRATE, INTRAVENOUS | 300 mg/15 mL |
Last updated: Jan. 9, 2024
- Black Box Warning: Progressive multifocal leukoencephalopathy (PML)
- REMS: Tysabri Intraveneous Injection
- Restricted Restricted Medication
This medication is Inpatient Non-formulary and Restricted to Outpatient Use. Inpatient use requires approval by a physician department leader (i.e. Medical Director or Chair, or hospital CMO) collaborating with a pharmacy leader. See the review for details.
See HERE for more information and workflow.
See HERE for additional pharmacy workflow details.
Only prescribers and patients enrolled in TOUCH Program can prescribe and receive TYSABRI.
Mandatory surveillance program required.